rosiglitazone has been researched along with Kidney Failure, Chronic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chernichovski, T; Filip, I; Ingbir, M; Levin-Iaina, N; Levo, Y; Reshef, R; Rozovski, U; Schwartz, D; Schwartz, IF; Shtabsky, A | 1 |
| Aramwit, P; Sriboonruang, T; Supasyndh, O | 1 |
| Abdul Ghani, R; Kamaruddin, NA; Kong, NC; Zainudin, S | 1 |
| Albert, JM; Bailie, GR; Blayney, MJ; Goodkin, DA; Pisoni, RL; Port, FK; Ramirez, SP; Tentori, F; Wolfe, RA; Young, EW | 1 |
| Acar, G; Akcay, A; Citirik, C; Dogan, E; Sayarlioglu, H; Sokmen, A; Sokmen, G; Tuncer, C; Ucar, MA | 1 |
| Chan, DT; Dogra, GK; Irish, AB; Watts, GF | 1 |
| Grossman, E | 1 |
| Allcock, NM; Manley, HJ | 1 |
| Hsu, YJ; Hung, YJ; Kuo, SW; Lin, SH; Lin, YF | 1 |
| Duan, S; Liu, F; Liu, H; Liu, Y; Peng, Y; Wang, H | 1 |
| Bakris, GL; Sarafidis, PA | 1 |
2 review(s) available for rosiglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Topics: Albuminuria; Blood Pressure Determination; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Prognosis; Risk Assessment; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones | 2003 |
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone | 2006 |
2 trial(s) available for rosiglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Blood Proteins; Female; Half-Life; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Protein Binding; Rosiglitazone; Thiazolidinediones; Tissue Distribution | 2008 |
Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.
Topics: Adipokines; Adolescent; Adult; Aged; C-Reactive Protein; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Kidney Failure, Chronic; Lipids; Lipoproteins; Male; Middle Aged; Prognosis; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Vascular Stiffness; Young Adult | 2011 |
7 other study(ies) available for rosiglitazone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Rosiglitazone improves aortic arginine transport, through inhibition of PKCalpha, in uremic rats.
Topics: Animals; Aorta; Arginine; Biological Transport; Cationic Amino Acid Transporter 1; Disease Models, Animal; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Nitric Oxide; Protein Kinase C-alpha; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Uremia | 2008 |
Acute renal failure following the use of rosiglitazone in a chronic kidney disease patient.
Topics: Acute Kidney Injury; Aged; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Mycophenolic Acid; Renal Dialysis; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone is associated with mortality in chronic hemodialysis patients.
Topics: Aged; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Female; Hospitalization; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Renal Dialysis; Rosiglitazone; Thiazolidinediones | 2009 |
Effects of rosiglitazone on cardiac function in CAPD patients: a tissue Doppler study.
Topics: Adult; Blood Flow Velocity; Cohort Studies; Echocardiography, Doppler, Pulsed; Female; Heart Function Tests; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Probability; Prognosis; Prospective Studies; Reference Values; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2009 |
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.
Topics: Aged; Aged, 80 and over; Blood Pressure; Comorbidity; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Outpatients; Pioglitazone; Renal Dialysis; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2003 |
Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.
Topics: Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Case-Control Studies; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-6; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones | 2003 |
Inhibitory effect of PPAR-gamma activator on IL-6 and mPGES protein expression in PBMC induced by homocysteine.
Topics: Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Homocysteine; Humans; Interleukin-6; Intramolecular Oxidoreductases; Kidney Failure, Chronic; Leukocytes, Mononuclear; Microsomes; PPAR gamma; Prostaglandin-E Synthases; Renal Dialysis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |